65,437 trials
Knee Osteoarthritis
Primary: Change in Clinical Pain as Assessed by a Numeric Rating Scale for Pain (NRS) — -24.67; -3.33 score on a scale
Prostate Cancer
Primary: Progression Free Survival — 16.1 months
Active Non-segmental Vitiligo
Primary: Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period — -21.2; -21.2; -18.5; -14.6 Percent…
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R) — -21.3; -23.0; -23.1 score on a scale — p=0.2215
Pneumococcal Infections · Pneumococcal Vaccines
Primary: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) in V114 Versus Prevnar 13™ — 69.0; 69.2; 33.7; 38.5 Percentage of participants — p== 0.039
Paroxysmal Nocturnal Hemoglobinuria
Primary: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP — 2.37; -1.47 Grams per deciliter (g/dL) — p=<0.0001
Insomnia Disorder
Primary: Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance) — -15.31; -24.19; -12.57 minutes — p=0.0001
Clostridium Difficile Infection (CDI)
Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195
Pain, Neuropathic · Pain, Acute
Primary: VR Effect on Pain Tolerence — 135; 158 seconds — p=<0.001
Chronic Myeloid Leukemia
Primary: Percentage of Leukemic Stem Cells Present in Bone Marrow Aspirate Samples, in This Patient Population — 37.4; 2.32; 0.7; 7.04 percentage of leukemic stem cells
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3) — 64.2; 72.5 Percentage of Participants — p=0.1846
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Using the ETDRS Visual Acuity Chart at a Starting…
SARS-CoV-2 Virus Infection
Primary: Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series — 35; 31; 36; 32 events
Relapsed/Refractory B-cell Malignancies
Primary: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) — 100.0; 100.0; 100.0; 100.0 percentage of participants
Pain, Intractable · Breakthrough Pain · Chronic Pain
Primary: Change From Baseline in the Numerical Rating Pain Scale (NRS) — 1.87; 1.81 units on a scale